WARRICK 1621 (Griseofulvin (ultramicrocrystalline) 250 mg)
Pill imprint WARRICK 1621 has been identified as Griseofulvin (ultramicrocrystalline) 250 mg.
Griseofulvin is used in the treatment of tinea capitis; dermatophytosis; tinea barbae; tinea corporis; onychomycosis, fingernail (and more), and belongs to the drug class miscellaneous antifungals. Risk cannot be ruled out during pregnancy. Griseofulvin 250 mg is classified as a Schedule N controlled substance under the Controlled Substance Act (CSA).
More about griseofulvin
- Griseofulvin microsize oral suspension
- Griseofulvin microsize tablets
- Griseofulvin ultramicrosize tablets
- Griseofulvin (Advanced Reading)
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2015 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.